BDNF Release Is Required for the Behavioral Actions of Ketamine
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies demonstrate that the rapid antidepressant ketamine increases spine number and function in the medial prefrontal cortex (mPFC), and that these effects are dependent on activation of glutamate α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors and brain-derived neurotrophic factor (BDNF). In vitro studies also show that activation of AMPA receptors stimulates BNDF release via activation of L-type voltage-dependent calcium channels (VDCC). METHODS: Based on this evidence, we examined the role of BDNF release and the impact of L-type VDCCs on the behavioral actions of ketamine. RESULTS: The results demonstrate that infusion of a neutralizing BDNF antibody into the mPFC blocks the behavioral effects of ketamine in the forced swim test (FST). In addition, we show that pretreatment with nifedipine or verapamil, two structurally-different L-type calcium channel antagonists, blocks the behavioral effects of ketamine in the FST. Finally, we show that ketamine treatment stimulates BDNF release in primary cortical neurons and that this effect is blocked by inhibition of AMPA receptors or L-type VDCCs. CONCLUSIONS: Taken together, these results indicate that the antidepressant effects of ketamine are mediated by activation of L-type VDCCs and the release of BDNF. They further elucidate the cellular mechanisms underlying this novel rapid-acting antidepressant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of AMPA receptors and L-VDCCs is essential for the rapid release of BDNF [68].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, conditional knockout of BDNF in forebrain regions increases depressive behavior in females, but not in male mice [222], and blocks the effects of antidepressants desipramine or ketamine [216,223].”
From Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer (2020) · cites this paper as [216]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ketamine treatment (0.5 μM) facilitated BDNF release from primary cortical neurons 15, 60, and 360 minutes post-treatment”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lepack et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“infusion of an anti-BDNF antibody into the mPFC blocked the antidepressant-like effects of ketamine (10 mg/kg i.p.) in the forced swim test”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lepack et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“These procedures and doses have been validated in previous studies (7, 8, 34, 35).”
From Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation (2019) · cites this paper as [34]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 2×
“…There are no competing financial interests in relation to the work described. uthor M anuscript A uthor M anuscript A uthor M anuscript Introduction Depression is a debilitating and costly illness that affects approximately 17% of the population at some point in life (Kessler et al., 2003).”
BackgroundDomingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“The Met allele impairs activity-dependent BDNF release (Egan et al., 2003; Chen et al., 2004), and is associated with increased susceptibility to depression (Sen et al., 2003; Gatt et al., 2009).”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Although there are several different classes of antidepressants available, these medications can take several weeks to months to produce a therapeutic response, and approximately one-third of depressed patients are nonresponsive and considered treatment resistant (Trivedi et al., 2006).”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 14×
“The antidepressant actions of ketamine are blocked by pretreatment with a glutamate-AMPA receptor antagonist (Maeng et al., 2008; Li et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“The rapid and long-lasting behavioral effects of ketamine are blocked in conditional BDNF-deletion mutant mice (Autry et al., 2011) and in BDNF Val66Met knock-in mice (Liu et al., 2012).”
BackgroundResultInfluentialSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“This contrasts with the actions of typical antidepressants, which require chronic administration and only regulate expression, not release, of BDNF (Duman and Aghajanian, 2012).”
BackgroundSelf-citationNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“BDNF has been shown to play an important role in neuropsychiatric disorders, including the pathophysiology and treatment response to typical antidepressants (Chen et al., 2001; Duman and Monteggia, 2006; Martinowich et al., 2007).”
BackgroundIncreased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Chen, Z.-Y., Patel, P. D., Sant, G., Meng, C.-X., Teng, K. K., Hempstead, B. L., & Lee, F. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0348-04.2004 · Cited by 874
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 1×
“Recent clinical studies demonstrate that a single, low dose of ketamine, an N-methyl-D-asparate (NMDA) receptor antagonist, produces a rapid and long-lasting antidepressant response in treatmentresistant patients (Berman et al., 2000; Zarate et al., 2006; Price et al., 2009).”
BackgroundGatt, J. M., Nemeroff, C. B., Dobson-Stone, C., Paul, R. H., Bryant, R. A., Schofield, P. R., Gordon, E., Kemp, A. H., & Williams, L. M. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.143 · Cited by 525 · cited 2×
“, 2004), and is associated with increased susceptibility to depression (Sen et al., 2003; Gatt et al., 2009).”
BackgroundLiu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Self-citationSen, S., Nesse, R. M., Stoltenberg, S. F., Li, S., Gleiberman, L., Chakravarti, A., Weder, A. B., & Burmeister, M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300053 · Cited by 332
Voleti, B., Navarria, A., Liu, R.-J., Banasr, M., Li, N., Terwilliger, R., Sanacora, G., Eid, T., Aghajanian, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.025 · Cited by 264
Self-citationBDNF activates mTOR to regulate GluR1 expression required for memory formation
Slipczuk, L., Bekinschtein, P., Katche, C., Cammarota, M., Izquierdo, I., & Medina, J. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006007 · Cited by 246
Jourdi, H., Hsu, Y.-T., Zhou, M., Qin, Q., Bi, X., & Baudry, M. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6078-08.2009 · Cited by 226 · cited 7×
“A previous study in cultured neurons reported that AMPA-stimulation of BDNF release is blocked by L-type VDCC antagonists (Jourdi et al., 2009).”
BackgroundInfluentialmTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169 · cited 1×
“This includes antagonists of the mGlu2/3 receptor (e.g., LY 341495) and muscarinic receptor (e.g., scopolamine) that produce behavioral effects similar to ketamine and that are also dependent on mTORC1 activation (Dwyer et al., 2012; Voleti et al., 2013).”
Self-citationCain, C. K., Blouin, A. M., & Barad, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09113.2002 · Cited by 130 · cited 2×
“…hour following injection) and verapamil (30 and 60 min following injection) do not have an effect on locomotor activity, indicating the effects seen in the FST were not due to a generalized decrease in ambulation for the groups receiving a channel blocker (Borroni et al., 2000; Cain et al., 2002).”
BackgroundBorroni, A. M., Fichtenholtz, H., Woodside, B. L., & Teyler, T. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09272.2000 · Cited by 100
Woodside, B. L., Borroni, A. M., Hammonds, M. D., & Teyler, T. J. (2004) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2003.10.003 · Cited by 98
Seoane, A., Massey, P. V., Keen, H., Bashir, Z. I., & Brown, M. W. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5199-08.2009 · Cited by 73
Cited by
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Metadata
- Authors
- Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, R. S.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-31
- Volume
- 18
- Issue
- 1
- Pages
- pyu033-pyu033
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4368871
- OpenAlex
- W2134458928
- Cited by
- 368
- References
- 27
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 26 · 2023: 26 · 2022: 34 · 2021: 34 · 2020: 44 · 2019: 53 · 2018: 40 · 2017: 33 · 2016: 26 · 2015: 16
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (MH093897, R01MH093897, R01MH105910)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine, brain-derived neurotrophic factor, BDNF release, L-type voltage-dependent calcium channels, AMPA receptors, rapid-acting antidepressants, medial prefrontal cortex, forced swim test, nifedipine, verapamil, primary cortical neurons
- MeSH terms
- Animals, Antidepressive Agents, Calcium Channel Blockers, Cells, Cultured, Depressive Disorder, Ketamine, Male, Neurons, Nifedipine, Verapamil, Rats, Sprague-Dawley, Prefrontal Cortex, Receptors, AMPA, Brain-Derived Neurotrophic Factor, Calcium Channels, L-Type
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.